Stryker's $25B Medtech Empire Hit by Iranian Cyberattack While Mako Robotics Franchise Expands Into New Territory

Stryker just posted its fourth consecutive year of double-digit organic growth, surpassing $25B in revenue, but a devastating pro-Iran cyberattack wiped 200,000+ devices and disrupted global manufacturing. The company is simultaneously launching Mako RPS — a handheld surgical robot — and building an AI-powered SmartHospital platform that could redefine clinical workflows.

SYK · Health Care · March 25, 2026

S&P 500 Position

Stryker sits behind UnitedHealth, J&J, Eli Lilly, AbbVie, and Abbott within the Health Care sector, but trades at a premium to most medtech peers. Its $126B market cap places it well above Zimmer Biomet (~$22B) and CONMED (~$3B), and in a peer tier with Boston Scientific (~$130B) and Medtronic (~$105B). Among dedicated medical device companies, Stryker commands the highest organic growth rate and one of the richest valuations.

Index Weight: ~0.21% | Rank: Approximately #60-70 in the S&P 500 by market cap

Company Overview

Stryker is operating on two tracks right now: executing one of medtech's strongest organic growth stories while recovering from the most significant cyberattack to hit a U.S. medical device company in memory. The March 11, 2026 breach by pro-Iran hacktivist group Handala wiped over 200,000 devices across 79 countries using a 'living off the land' technique — exploiting Stryker's own Microsoft Intune environment to issue remote wipe commands rather than deploying traditional malware. Order processing, manufacturing, and shipping were disrupted for weeks. Palo Alto Networks' Unit 42 is running the forensic investigation, and CISA issued a nationwide advisory urging other Microsoft Intune users to harden endpoint security. A class action lawsuit has already been filed. Pre-attack, Stryker was on fire. FY2025 delivered $25.1B in revenue (up 11.2% YoY), the fourth straight year of double-digit organic growth — a streak nearly unmatched in medtech. The Mako surgical robotics franchise now has over 3,000 installations worldwide, powers two-thirds of Stryker's U.S. knee procedures, and is expanding into shoulder (now in full market release) and spine. The new Mako RPS handheld robot, cleared by FDA in August 2025, targets the segment of surgeons who want robotic precision without leaving their manual workflow. Simultaneously, the SmartHospital platform — built on the $3B Vocera acquisition and the care.ai ambient intelligence buy — represents Stryker's play to become the operating system of the hospital room, connecting beds, communication badges, ambient sensors, and workflow engines into a single AI-driven ecosystem. Strategically, CEO Kevin Lobo's dual-engine model of organic innovation plus tuck-in M&A continues to compound. The $4.9B Inari Medical acquisition (closed February 2025) gave Stryker a peripheral vascular franchise with high-teens procedural growth. The new COO appointment of 27-year veteran Spencer Stiles signals succession planning and operational continuity, while Lobo himself was just appointed to GE HealthCare's board. The 2026 guidance of 8-9.5% organic growth and $14.90-$15.10 adjusted EPS was set before the cyberattack — the real question is how much Q1 manufacturing disruption eats into that target.

Products & Revenue

Stryker generates $25.1B in annual revenue across two reportable segments. MedSurg and Neurotechnology is the growth engine at $15.6B (62.3% of revenue), up 15.7% YoY, covering everything from surgical instruments and endoscopy to emergency medical equipment, the Vocera/care.ai clinical communication platform, neurovascular stroke devices, and the newly acquired Inari Medical vascular portfolio. Orthopaedics at $9.5B (37.7%) grew a more modest 4.3%, driven by trauma and extremities (12.6% growth) and strong Mako-driven gains in knees (8.5%) and hips (9.5%). The Mako robotic system is a razor-and-blade model: Stryker places ~$1M+ systems in hospitals, then captures long-tail implant revenue on every procedure.

MedSurg and Neurotechnology — Instruments (~12.7%): Surgical equipment, navigation systems (including Stryker NAV3 platform), power tools for orthopedic and surgical procedures, and the new Steri-Shield 8 protective system. Grew 12.3% in FY2025.

MedSurg and Neurotechnology — Endoscopy (~15.1%): 4K camera platforms (1788 system), Connected OR integration suite (BRAVoE), visualization technologies for arthroscopy, urology, and neurology. Includes the new dedicated breast care sales force.

MedSurg and Neurotechnology — Medical (~16.7%): Hospital beds (ProCuity), stretchers (Prime Connect), defibrillators, EMS equipment (including LIFENET), intensive care disposables, and the SmartHospital/SmartCare platform (Vocera + care.ai). Houses the new SmartCare business unit.

MedSurg and Neurotechnology — Neuro Cranial & Vascular (~17.8%): Neurosurgical and neurovascular devices for stroke treatment, craniomaxillofacial implants, orthobiologics, and the Inari Medical peripheral vascular portfolio (venous thromboembolism devices). Neuro Cranial alone grew 16.3% in FY2025.

Orthopaedics — Knees & Hips (~18.0%): Triathlon knee system (including new Triathlon Gold with titanium nitride coating), hip implant portfolio, and the Mako SmartRobotics platform (Mako 4 and Mako RPS). Over 3,000 Mako systems installed globally.

Orthopaedics — Trauma, Extremities & Other (~19.7%): Fracture fixation systems, extremity implants, shoulder replacements (Tornier), and Mako Shoulder/Spine applications. Trauma & extremities was the fastest-growing ortho sub-segment at 12.6% in FY2025.

Based on FY2025 10-K filing (period ending December 31, 2025) and Q4 2025 earnings release dated January 29, 2026. Sub-segment percentages are approximate based on reported figures.

Leadership

Kevin A. Lobo

CEO since 2012. Lobo has been CEO since October 2012 and Chair since July 2014, presiding over Stryker's revenue growth from $8B to $25B+ through more than 60 acquisitions. His pre-Stryker career spans eight years at Johnson & Johnson (including as President of Ethicon Endo Surgery and CFO of McNeil Consumer Healthcare) plus roles at Rhône-Poulenc, Kraft Canada, Unilever, and KPMG. Recently appointed to GE HealthCare's board of directors in March 2026.

Spencer Stiles, President and Chief Operating Officer: Appointed COO effective January 1, 2026 — a 27-year Stryker veteran who previously led Orthopaedics and Spine since 2019. Now oversees all global businesses, strategy, and M&A execution. His appointment is widely read as succession planning.

J. Andrew Pierce, Group President, MedSurg and Neurotechnology: Leads Stryker's largest segment ($15.6B), including the SmartCare business unit, the Inari Medical integration, and the endoscopy franchise. Drove the care.ai acquisition and SmartHospital platform strategy.

Keith Evans, Vice President and General Manager, Mako and Enabling Technologies: Runs the Mako robotics franchise — from the flagship Mako 4 system to the new Mako RPS handheld robot and the expansion into shoulder and spine applications. Overseeing the limited market release of Mako RPS in 2026.

Preston Wells, Vice President and Chief Financial Officer: Succeeded Glenn Boehnlein as CFO in April 2025 after serving as Group CFO for Orthopaedics. Previously held finance roles at Dialight Corporation and Johnson & Johnson for 17 years. Managing the financial impact of the March 2026 cyberattack.

Jessica Mathieson, President, Medical Business: Leads Stryker's ~$4B Medical division and the newly formed Smart Care business unit that combines Vocera and care.ai. Architecting the SmartHospital platform that connects 85+ Stryker products into a single digital ecosystem.

The AI Angle

Building the operating system of the smart hospital

Stryker's AI strategy runs across two distinct domains: robotic-assisted surgery and ambient hospital intelligence. On the robotics side, the Mako SmartRobotics platform uses 3D CT-based preoperative planning and AccuStop haptic technology to create patient-specific surgical boundaries that guide surgeons through joint replacement, spine, and now shoulder procedures. The fourth-generation Mako 4 system integrates the Q Guidance System, built on 20+ years of navigation technology development, and each procedure generates volumetric data that feeds back into planning algorithms. With over 1.5 million Mako procedures performed across 45 countries, Stryker possesses one of the largest proprietary datasets of orthopedic surgical outcomes in existence — a significant moat for training future ML models. The new Mako RPS handheld robot extends the same IP into a form factor that uses haptic boundaries on a manual power tool, targeting the ~30% of U.S. knee surgeons who haven't adopted robotic arms. The second AI pillar is SmartHospital, launched in March 2026 as the product of Stryker's acquisitions of Vocera Communications ($2.97B, 2022) and care.ai (2024). This is not a single product but a platform architecture: care.ai's ambient intelligence sensors use computer vision and AI to monitor patient rooms — detecting fall risks, pressure injury development, and workflow events — while the Vocera Engage middleware acts as an intelligent routing layer that integrates with 150+ clinical systems (EHRs, nurse call, monitors) to filter, prioritize, and deliver alerts to the right caregiver via Sync Badge or smartphone. The closed-loop workflow is the key innovation: a care.ai sensor detects a patient attempting to leave their ProCuity bed, the Vocera middleware intercepts and routes a targeted alert to the assigned nurse's badge, eliminating alarm fatigue and enabling what Stryker calls 'silent, closed-loop' clinical workflows. The newly formed SmartCare business unit within the Medical division houses this combined capability. Stryker's AI approach is build-and-buy rather than partnership-dependent. The Mako platform was built on the 2013 acquisition of MAKO Surgical Corp, and Stryker has invested continuously in its proprietary software stack. The care.ai platform brings its own AI engineering team and sensor hardware. Stryker does not rely on external AI model providers for its core clinical applications — the intelligence is embedded in device firmware and edge computing, which is critical for latency-sensitive surgical and patient monitoring use cases. The competitive risk is real. Zimmer Biomet's Rosa robot is gaining traction in knees, Johnson & Johnson is pushing its Ottava system, and Intuitive Surgical dominates soft tissue robotics. In hospital intelligence, competitors like GE HealthCare and Philips are building their own connected care platforms. Stryker's advantage is integration depth: it owns the beds, the stretchers, the communication layer, the sensors, and the robotics — no competitor has this end-to-end stack. The March 2026 cyberattack, however, exposed a critical vulnerability: the SmartHospital value proposition depends on always-on connectivity, and a breach that takes down the Microsoft corporate environment — even without touching product systems — undermines customer confidence in entrusting more hospital infrastructure to a single vendor.

Financial Snapshot

Revenue (TTM): $25.1B — TTM (period ending Dec 31, 2025) | Net Income: $3.25B

Margins: Gross 61.4%, adjusted operating 30.2% (Q4), GAAP operating ~22.4%, net 12.9%

Stryker delivered 100+ basis points of adjusted operating margin expansion for the second consecutive year despite ~$400M in projected tariff headwinds for 2026. Capital allocation remains acquisition-heavy: $4.9B for Inari Medical, plus ongoing tuck-ins like care.ai and Artelon. The $3.52 annual dividend (1.0% yield) is token — this is a growth-and-reinvest story. Free cash flow of $4.28B provides ample dry powder for additional M&A.

1-Year Performance

$327.65 as of March 25, 2026 — down 11.3% YoY, trading near its 52-week low

The stock has fallen ~19% from its July 2025 all-time closing high of $401.61. Two forces drove the decline: broader market rotation away from premium-multiple healthcare names in late 2025, and the March 11 cyberattack which triggered an immediate ~4% drop and continued selling pressure as the scope of the breach became clear. Pre-attack, the stock was already under pressure from tariff concerns ($400M projected 2026 impact) despite strong Q4 2025 earnings that beat on both revenue and EPS. Analysts maintain a consensus Buy rating with a median price target around $426, implying ~30% upside — but that target was set before the cyberattack's full impact on Q1 operations was understood.

Recent News

Fun Fact: The first prototype of Stryker's iconic oscillating cast saw — the product that launched the company's surgical instruments franchise — was built using a motor cannibalized from a malted milk mixer. Dr. Homer Stryker's insight was that an oscillating (rather than rotating) blade could cut through hard plaster cast material without slicing the soft tissue underneath. That same oscillation principle underpins Stryker's power tools business 80+ years later. Also: Dr. Stryker was the starting pitcher for the University of Michigan baseball team and led them to a Big Ten title before becoming a surgeon, and he had to delay medical school for two years because he failed the French language entrance exam.